MEDFORD, NY -- (Marketwire) -- 06/19/12 -- Chembio Diagnostics, Inc. (NASDAQ: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, reported today that data from a study evaluating performance characteristics (sensitivity and specificity) of three pre-market rapid point-of-care tests (one oral fluid and two finger-stick assays) in settings providing services to young adults who inject drugs was recently published online in the Journal of Clinical Virology and is expected to be published in the July 2012 print edition. The study authors concluded that the Chembio blood rapid assay, which is currently in development, demonstrated acceptable sensitivity and specificity, and was comparable to conventional assays currently in use. The complete article, "Field-based performance of three pre-market rapid hepatitis C virus (HCV) antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA," can be accessed online at http://www.sciencedirect.com/science/article/pii/S1386653212001333.
The study was designed to assess the performance of three recently developed rapid anti-HCV assays that had undergone both a laboratory-based validation and a field evaluation. The Chembio DPP® HCV finger-stick blood and oral fluid tests were evaluated. The rapid assays evaluated were single use, disposable, in vitro, qualitative, immuno-chromatographic assays to detect anti-HCV with visual results in less than 40 minutes. Behavioral risk assessment surveys and testing for HCV were conducted among persons who reported injection drug use (IDU) within the past 6 months as part of the Study to Assess Hepatitis C Risk (STAHR) among people who inject drugs (PWID) aged 18-40 years in 2009-2010. Sensitivity and specificity of the rapid anti-HCV assays were evaluated among STAHR participants, using two commonly used testing algorithms.
The study results showed that Chembio DPP® HCV finger-stick blood test had a sensitivity of 92.8% against a laboratory-based enzyme immunoassay (EIA) screening assay reference while it demonstrated 97.1% sensitivity against The Centers for Disease Control and Prevention (CDC) reference method algorithm which utilizes a third generation recombinant immunoblot assay (RIBA). The DPP® finger-stick blood test achieved 99.0% specificity on both reference methods. The study concluded, "We found further evidence that sensitive rapid anti-HCV assays can be useful for the detection of anti-HCV among persons at risk for HCV, such as PWID who can be reached through specific social service settings, such as syringe exchange programs. Of the three assays evaluated, the Chembio blood rapid assay demonstrated acceptable sensitivity and specificity, and was comparable to conventional assays currently in use."
Commenting on the study, Lawrence Siebert, Chembio's Chief Executive Officer, noted, "We are pleased that these data independently confirm that our DPP® HCV rapid assay, which is currently in development, demonstrated acceptable sensitivity and specificity in this HCV population and is comparable to conventional assays currently in use that may take weeks to provide results. These findings give us confidence that with additional time and resources we can develop a superior product for this important market."
Most Popular Stories
- Boehner Lashes Out Against Ted Cruz, Far Right
- TFA Recruiting DACA Recipients
- Hawaii Official Who Release Obama Certificate Only Victim of Plane Crash
- Holiday Shopping Off to a Slow Start This Season
- Ford Plans New Cars, Jobs in 2014
- Gold, Silver Slide on Prospects of Fed Exit
- 'Rape Insurance' Bill Passes in Michigan
- Ted Cruz Coloring Book Selling Briskly
- Kim Jong Un's Uncle Executed
- Grizzly Bears Could Be Taken Off Endangered List